1. Determining the role of radiotherapy in the adjuvant management of gastric cancer: an ocean apart

   • Benjamin W. Corn
   • Ravit Geva

   Editorial 20 February 2010 Pages: 1005 - 1007

2. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer

   • Aristotelis Bamias
   • M. Karina
   • G. Fountzilas

   Original Article 04 February 2010 Pages: 1009 - 1021

   

3. Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer

   • Matthew K. Wong
   • Alvis I. Lo
   • James C. Ho

   Original Article Open access 13 August 2009 Pages: 1023 - 1028

   

4. Beneficial effect of metronomic chemotherapy on tumor suppression and survival in a rat model of hepatocellular carcinoma with liver cirrhosis

   • Seong Tae Park
   • Jeong Won Jang
   • Seung Kew Yoon

   Original Article 23 August 2009 Pages: 1029 - 1037

   

5. LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate

   • Andre Luiz Mencalha
   • B. Du Rocher
   • E. Abdelhay

   Original Article 23 August 2009 Pages: 1039 - 1046

   

6. Differential roles of Trk and p75 neurotrophin receptors in tumorigenesis and chemoresistance ex vivo and in vivo

   • Muriel Bassili
   • Elena Birman
   • H. Uri Saragovi

   Original Article 22 August 2009 Pages: 1047 - 1056

   

7. Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients

   • Gareth J. Veal
   • Michael Cole
   • Alan V. Boddy

   Original Article 23 August 2009 Pages: 1057 - 1066

   

8. The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines

   • Allison Pledgie-Tracy
   • Madhavi Billam
   • Nancy E. Davidson

   Original Article 30 August 2009 Pages: 1067 - 1081

   

9. In vitro comparison of O4-benzylfolate modulated, BCNU-induced toxicity in human bone marrow using CFU-GM and tumor cell lines

   • Holger Peter Behrsing
   • Michael J. Furniss
   • Ralph E. Parchment

   Original Article 29 August 2009 Pages: 1083 - 1091

   

10. Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study

    • Wasaburo Koizumi
    • Toshikazu Akiya
    • Minoru Kurihara

    Original Article 30 August 2009 Pages: 1093 - 1099

    

11. Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer

    • Takashi Sasaki
    • Hiroyuki Isayama
    • Masao Omata

    Original Article 26 August 2009 Pages: 1101 - 1107

    

12. Pharmacokinetics and enhanced bioavailability of candidate cancer preventative agent, SR13668 in dogs and monkeys

    • Izet M. Kapetanovic
    • Miguel Muzzio
    • David L. McCormick

    Original Article 16 September 2009 Pages: 1109 - 1116

    

13. Oxidative stress and enhanced paracellular permeability in the small intestine of methotrexate-treated rats

    • Tomoko Maeda
    • Yuko Miyazono
    • Toshiharu Horie

    Original Article 16 September 2009 Pages: 1117 - 1123

    

14. Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias

    • Robin E. Norris
    • Peter C. Adamson

    Original Article 27 September 2009 Pages: 1125 - 1130

    

15. PSC833, cyclosporine analogue, downregulates MDR1 expression by activating JNK/c-Jun/AP-1 and suppressing NF-κB

    • H. Bark
    • Cheol-Hee Choi

    Original Article 18 September 2009 Pages: 1131 - 1136

    

16. Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series

    • Liliana Montella
    • Raffaele Addeo
    • Salvatore Del Prete

    Original Article 16 September 2009 Pages: 1137 - 1143

    

17. Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice

    • Pradeep B. Lukka
    • James W. Paxton
    • Bruce C. Baguley

    Original Article 23 September 2009 Pages: 1145 - 1152

    

18. Heterogeneity of epithelial and stromal cells of head and neck squamous cell carcinomas in ex vivo chemoresponse

    • Iris-Susanne Horn
    • Gunnar Wichmann
    • Andreas Boehm

    Original Article 22 September 2009 Pages: 1153 - 1163

    

19. Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data

    • Anne von Heideman
    • Åke Berglund
    • Peter Nygren

    Original Article 30 September 2009 Pages: 1165 - 1172

20. Medulloblastoma in childhood: revisiting intrathecal therapy in infants and children

    • Sharon Conroy
    • Martin Garnett
    • David Walker

    Original Article 24 October 2009 Pages: 1173 - 1189

21. Novel d-erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics

    • James W. Antoon
    • Jiawang Liu
    • Barbara S. Beckman

    Short Communication 14 February 2010 Pages: 1191 - 1195

    

22. Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer

    • Orazio Caffo
    • Stefania Fallani
    • Enzo Galligioni

    Short Communication 06 February 2010 Pages: 1197 - 1202

23. Population pharmacokinetic study of a test dose oral busulfan in Japanese adult patients undergoing hematopoietic stem cell transplantation

    • Yasushi Takamatsu
    • Noriaki Sasaki
    • Kazuo Tamura

    Short Communication 19 February 2010 Pages: 1203 - 1207